Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Eptifibatide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 known ✓ | P05106 | 5/20 | 1.00 |
| ▸ | ITGA2B known ✓ | P08514 | 3/20 | 1.00 |
| ▸ | ITGAV | P06756 | 5/20 | 1.00 |
| ▸ | MC3R | P41968 | 5/20 | 0.59 |
| ▸ | MC5R | P33032 | 4/20 | 0.59 |
| ▸ | MC4R | P32245 | 3/20 | 0.59 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.57 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.57 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.57 |
| ▸ | LDLR | P01130 | 9/20 | 0.57 |
| ▸ | PCSK9 | Q8NBP7 | 9/20 | 0.57 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eptifibatide SCHEMBL22193879 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| Eptifibatide SCHEMBL43237 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| Eptifibatide SCHEMBL18504808 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| Eptifibatide SCHEMBL16883987 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| Eptifibatide SCHEMBL16884017 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| Eptifibatide SCHEMBL29353236 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGA2BMC3RMC5R | |
| SCHEMBL29356871 | 0.98 | ITGB3 (0.97) | ITGB3ITGAVITGA2BMC3RMC5R | |
| SCHEMBL16883997 | 0.93 | ITGB3 (0.87) | ITGB3ITGAVITGA2BLDLRPCSK9 | |
| SCHEMBL24433345 | 0.93 | ITGB3 (0.86) | ITGB3ITGAVITGA2BMC3RMC5R | |
| SCHEMBL16883930 | 0.91 | ITGB3 (0.84) | ITGB3ITGAVITGA2BMC3RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12466851-B2 | Manufacture of disulfide bonded peptides | BACHEM HOLDING AG (CH) | 2025-11-11 | — | — | US | disclosed |
| EP-4381284-B1 | LIGAND-TARGET INTERACTION ANALYSIS BY PHOTOCHEMICALLY INDUCED DYNAMIC NUCLEAR POLARIZATION (PHOTO-CIDNP) ENHANCED NMR SPECTROSCOPY | ETH ZUERICH (CH) | 2025-07-09 | — | — | EP | disclosed |
| US-20250076319-A1 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2025-03-06 | — | — | US | disclosed |
| US-20240350465-A1 | METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2024-10-24 | — | — | US | disclosed |
| EP-4380685-A1 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | University of Vermont and State Agricultural College (US) | 2024-06-12 | — | — | EP | disclosed |
| EP-4380603-A1 | METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT | University of Vermont and State Agricultural College (US) | 2024-06-12 | — | — | EP | disclosed |
| WO-2023015230-A1 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014354-A1 | METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT | THE UNIVERSITY OF VERMONT AND STATE AGRICULTURE COLLEGE (US) | 2023-02-09 | — | — | WO | disclosed |
| US-20220213139-A1 | MANUFACTURE OF DISULFIDE BONDED PEPTIDES | BACHEM HOLDING AG (CH) | 2022-07-07 | — | — | US | disclosed |
| CN-104710509-A | Eptifibatide preparation method | SHENZHEN HYBIO PHARMACEUTICAL | 2015-06-17 | — | — | CN | disclosed |
| US-8962638-B2 | Piperidine inhibitors of janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| CN-102702320-B | Method for preparing eptifibatide | SHENZHEN HYBIO PHARMACEUTICAL | 2013-08-21 | — | — | CN | disclosed |
| CN-102702320-A | Method for preparing eptifibatide | SHENZHEN HYBIO PHARMACEUTICAL | 2012-10-03 | — | — | CN | disclosed |
| CN-101538314-B | Method for purifying Eptifibatide | SHENZHEN HYBIO PHARMACEUTICAL | 2012-10-03 | — | — | CN | disclosed |
| CN-101538316-B | Method for preparing Eptifibatide with solid phase method | SHENZHEN HYBIO PHARMACEUTICAL | 2012-09-05 | — | — | CN | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| CN-101538316-A | Method for preparing Eptifibatide with solid phase method | SHENZHEN HANYU PHARMACEUTICAL | 2009-09-23 | — | — | CN | disclosed |
| CN-101538314-A | Method for purifying Eptifibatide | SHENZHEN HANYU PHARMACEUTICAL | 2009-09-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240350465-A1 | METHODS FOR SELECTING AN INTRACRANIAL ATHEROSCLEROTIC DISEASE PATIENT FOR TREATMENT | PCSK9, APOB, PCSK7 | ITGB3 413/4885ITGA2B 165/4885ITGAV 361/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | ITGB3 1125/4885ITGA2B 1286/4885ITGAV 1364/4885 |
| US-20250076319-A1 | METHODS FOR SELECTING A CANCER PATIENT FOR TREATMENT | SERPINC1, SELP, ADAMTS13 | ITGB3 95/4885ITGA2B 188/4885ITGAV 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.